Current treatments of anxiety disorders

November 14, 2016
6019
Specialities :
Resume

The group of anxiety disorders, according with the International Classification of Diseases-10, includes generalized anxiety disorder, panic disorder, specific fobias and social anxiety disorder, is a common problem with lifetime prevalence in every fifth inhabitant of the developed countries. One of the most problematic conditions in context of effective treatment is generalized anxiety disorder which is characterized by continuous excessive worrying about number of nonspecific events or activities. Approximately ⅓ of all patients do not respond to antidepressants. Modern guidelines started to recommend other drug groups for management of anxiety. One of such groups is antiepileptic drugs, particularly pregabalin. The current state of problem and cases in which alternative treatment can be useful has been analyzed in the review.

Published: 14.11.2016

References:

  • AAFP (2015) Diagnosis and Management of Generalized Anxiety Disorder and Panic Disorder in Adults (http://www.aafp.org/afp/2015/0501/p617.html).
  • APA (2009) Practical Guideline for the treatment of patients with panic disorders (http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/panicdisorder.pdf).
  • Baxter A.J., Vos T., Scott K.M. et al. (2014) The global burder of anxiety disorders in 2010. Psychol. Med., 44(11): 2363–2374.
  • Cegin M.B., Soyoral L., Yuzkat N. et al. (2016) Pregabalin administered as an anxiolytic agent in ultrasound-guided infraclavicular block: a controlled, double-blind, dose-ranging trial. European Review for Medical and Pharmacological Sciences, 20: 568–574.
  • Kessler R.C., McGonagle K.A., Zhao S. et al. (1994) Lifetime and 12-Month Prevalence of DSM-III-R Psychiatric Disorders in the United States. Arch. Gen. Psych., 51: 8–19.
  • NICE (2014) Anxiety disorders. Quality standard [QS53] (https://www.nice.org.uk/guidance/qs53/chapter/Quality-statement-3-Pharmacological-treatment).
  • Perna G., Alciaty A., Riva A. et al. (2016) Long-Term Pharmacological Treatments of Anxiety Disorders: An Updated Systematic Review. Curr. Psychiatry Rep., 18: 23.
  • Sadosky A., Parsons B., Emir B., Nielshoff E.C. (2016) Pain relief and functional improvement in patients with neuropathic pain associated with spinal cord injury: an exploratory analysis of pregabalin clinical trials. J. Pain Res., 9: 405–416.
  • Tsang A., Von Korff M., Lee S. et al. (2008) Common Chronic Pain Conditions in Developed and Developing Countries: Gender and Age Differences and Comorbidity With Depression-Anxiety Disorders. J. Pain, 9(10): 883–891.